Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has a price-to-earnings ratio that is above its average at 13.26x. The stock has a 36-month beta value of 0.32. Opinions on the stock are mixed, with 14 analysts rating it as a “buy,” 6 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for REGN is 104.06M, and at present, short sellers hold a 1.95% of that float. On June 27, 2025, the average trading volume of REGN was 1.35M shares.
REGN) stock’s latest price update
The stock of Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has increased by 0.14 when compared to last closing price of 520.29. Despite this, the company has experienced a 1.44% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-26 that TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
REGN’s Market Performance
REGN’s stock has risen by 1.44% in the past week, with a monthly drop of -13.64% and a quarterly drop of -18.61%. The volatility ratio for the week is 2.09% while the volatility levels for the last 30 days are 3.06% for Regeneron Pharmaceuticals, Inc The simple moving average for the past 20 days is 1.39% for REGN’s stock, with a -28.78% simple moving average for the past 200 days.
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Wells Fargo repeating the rating for REGN by listing it as a “Equal Weight.” The predicted price for REGN in the upcoming period, according to Wells Fargo is $580 based on the research report published on May 30, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see REGN reach a price target of $662. The rating they have provided for REGN stocks is “Sector Perform” according to the report published on May 30th, 2025.
Citigroup gave a rating of “Buy” to REGN, setting the target price at $700 in the report published on May 14th of the current year.
REGN Trading at -6.14% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.98% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.85 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.32. The total capital return value is set at 0.11. Equity return is now at value 15.96, with 12.51 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 98.59.
Currently, EBITDA for the company is 5.32 billion with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 3.9. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
To sum up, Regeneron Pharmaceuticals, Inc (REGN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
